1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,103 | 0,115 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 11.12. | Viva Biotech Establishes New Branch in Boston | 2 | Contract Pharma | ||
| 11.12. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 11.12. | Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion | 186 | PR Newswire | HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in... ► Artikel lesen | |
| 02.12. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 14.11. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 06.11. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 30.10. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 15.10. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.10. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 27.09. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT COMPLETION OF JOINT-STOCK CONVERSION OF VIVA SHANGHAI AND CHANGE OF ROLES OF CO-CHIEF FINANCIAL OFFICER | - | HKEx | ||
| 26.09. | VIVA BIOTECH (01873): INTERIM REPORT 2024 | - | HKEx | ||
| 25.09. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 13.09. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 13.09. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS (REVISED) | 1 | HKEx | ||
| 05.09. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.08. | Viva Biotech Holdings: Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | 78 | PR Newswire | Results Highlights for Interim Results ended 30 June 2024
Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS... ► Artikel lesen | |
| 29.08. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE | - | HKEx | ||
| 29.08. | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
| 28.08. | VIVA BIOTECH (01873): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDER AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 1,933 | -0,51 % | Valneva: Kooperation für Chikungunya-Impfstoff in Asien | Valneva hat eine exklusive Lizenzvereinbarung mit dem Serum Institute of India (SII) getroffen, um seinen Chikungunya-Impfstoff in Asien verfügbar zu machen. Die Kooperation ermöglicht den Zugang zu... ► Artikel lesen | |
| NOVONESIS | 54,66 | -0,44 % | Novonesis (Novozymes A/S): Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% | Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance... ► Artikel lesen | |
| GENMAB | 197,35 | -1,30 % | Genmab A/S: Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | Results from Arm 1 of the EPCORE NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,030 | -1,05 % | Arbutus Biopharma Aktie: Abwarten statt Handeln | Die Arbutus Biopharma Corporation verzeichnet zum Jahresende 2024 eine bemerkenswerte Entwicklung an der Börse. Mit einem aktuellen Kurs von 3,08 EUR und einer Marktkapitalisierung von 460,9 Millionen... ► Artikel lesen | |
| BEIGENE LTD ADR | 171,00 | 0,00 % | BeiGene, Ltd.: BeiGene ändert am 2. Januar Nasdaq Tickersymbol in "ONC"; auf der 43. Annual J.P. Morgan Healthcare Conference präsent | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), ein globales Unternehmen für Onkologie, wird seinen Namen in BeOne Medicines Ltd. umwandeln. Es wird aus diesem Grund auch sein Nasdaq Tickersymbol... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,450 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia ... | Company on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025
Trial designed for possible... ► Artikel lesen | |
| VERICEL | 54,50 | -0,91 % | Vericel Corporation: Vericel Reports Third Quarter 2024 Financial Results | Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third... ► Artikel lesen | |
| SINO BIOPHARM | 0,389 | -0,71 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - PERMISSION OBTAINED TO SUBMIT MARKETING APPLICATION FOR THE INDICATION OF BENMELSTOBART INJECTION IN COMBINATION ... | ||
| SENSEI BIOTHERAPEUTICS | 0,422 | -3,65 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,339 | +1,47 % | BioXcel Therapeutics Aktie: Ein Wendepunkt ins Negative? | Die BioXcel Therapeutics Aktie verzeichnet zum Ende des Monats November 2024 eine bemerkenswerte Schwächephase. Der aktuelle Kurs von 0,39 EUR spiegelt einen signifikanten monatlichen Rückgang von 31... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,792 | +7,61 % | MustGrow Biologics Corp.: MustGrow Biologics Announces Proposed Private Placement of Units for Approximately $2 Million | Saskatoon, Saskatchewan--(Newsfile Corp. - December 11, 2024) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a proposed non-brokered... ► Artikel lesen | |
| ZAI LAB LTD ADR | 26,200 | +2,34 % | Zai Lab, Novocure Report Positive Topline Results From Phase 3 PANOVA-3 Trial Of TTFields Therapy | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Zai Lab (ZLAB) and Novocure (NVCR) announced that the Phase 3 PANOVA-3 trial met its primary endpoint, showing a statistically significant improvement in... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,276 | -2,13 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES SUBMISSION OF CLINICAL TRIAL APPLICATION IN AUSTRALIA FOR CS2009, AN INNOVATIVE PD-1/VEGF/CTLA-4 ... | ||
| AKEBIA | 1,789 | +0,90 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025
Over 300,000 patients, representing approximately 60% of dialysis patient... ► Artikel lesen | |
| REGENXBIO | 7,500 | +5,63 % | REGENXBIO Inc.: REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates | Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this... ► Artikel lesen |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,102 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.
